Treatment of Gynecomastia: First-Line Approach to Identifying and Resolving the Underlying Cause
Gynecomastia — benign enlargement of the male breast — is frequently driven by a correctable underlying condition or a causative medication. First-line management centres on identifying and removing that trigger before any further intervention is considered.
Clinical Approach
The initial evaluation aims to uncover a treatable underlying pathology or an implicated pharmaceutical agent — including anabolic androgenic steroids (AAS). Addressing the root cause is the primary objective before any other step is taken.
Treatment Direction
Management begins with treating any identifiable underlying pathology. Where a medication or substance is the suspected cause, modification or cessation is the recommended first step. The structured protocol specifies the sequencing, clinical decision points, and criteria for when to progress beyond this initial phase.
The complete regimen and decision algorithm are available via the link below.
Treatment Goal
The target outcome is spontaneous regression and full resolution of the breast enlargement — an achievable endpoint, particularly when the cause is identified and addressed early.
References
DOI: 10.1111/andr.12636
- Any underlying pathology should be treated, if possible (e.g., T substitution in case of T deficiency, and treatment of hyperthyroidism or hyperprolactinemia).
- If a pharmaceutical substance is suspected to be the cause, the medication should be changed or discontinued, if possible.
- In the case of AAS abuse, cessation of the substance should be encouraged.
- We recommend watchful waiting after treatment of underlying pathology or discontinuation of the administration/abuse of substances associated with GM.
- In cases of GM of puberty or GM of adulthood with negative physical and hormonal investigations, there is a fair chance that the condition will disappear spontaneously, especially if it is of recent onset.
View source ↗